Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) has signed a binding term sheet that could generate up to $259 million in licensing and sales milestone payments, plus ongoing royalties, as …
Ocugen Targets $259 Million in MENA Licensing Deal for OCU400 Read More MALVERN, PA — Ocugen (NASDAQ: OCGN) will present updates on its modifier gene therapy platform and clinical data from its retinal disease programs at a series of investor and industry …
Ocugen to Present Gene Therapy Data at July Conferences Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) recently closed a $130 million private offering of convertible senior notes, using part of the proceeds to retire existing debt while extending its …
Ocugen Extends Cash Runway With $130 Million Notes Read More MALVERN, PA — Ocugen (NASDAQ: OCGN) reported positive mid-stage clinical data for its geographic atrophy gene therapy program while raising additional capital expected to fund operations into 2028 as the …
Ocugen Reports Positive GA Trial Data, Extends Cash Runway Read More MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has completed enrollment and dosing in its Phase 2/3 clinical trial evaluating a gene therapy candidate for Stargardt disease.
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) reported fourth quarter and full-year 2025 financial results and provided updates on its clinical pipeline, including completion of enrollment for a Phase 3 …
Ocugen Reports 2025 Results and Clinical Progress Across Gene Therapy Pipeline Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced it has completed enrollment for the Phase 3 liMeliGhT clinical trial evaluating OCU400, a gene therapy candidate for retinitis pigmentosa, a group …
Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy Read More MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) will host a conference call and live webcast at 8:30 a.m. Eastern on Wednesday, March 4, 2026, to discuss its fourth-quarter and full-year …
Ocugen to Host March 4 Call on Q4 and Full-Year 2025 Results Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced the appointment of Rita Johnson-Greene as chief financial officer.
Ocugen Appoints Rita Johnson-Greene as Chief Financial Officer Read More MALVERN, PA — On Friday, Ocugen (Nasdaq: OCGN) closed a $22.5 million registered direct stock offering, strengthening its balance sheet as the gene-therapy developer pushes forward with programs targeting blinding …
Ocugen Raises $20.9M to Extend Cash Runway Into Late 2026 Read More